NPM1 and acute myeloid leukemia: The identification of FLT3-ITD, NPM1, and IDH1/2 have profoundly shifted diagnostic and therapeutic paradigms in AML, while data regarding the potential impact on prognosis and options for therapeutic targeting remain sparse for other somatic mutations.